Copper histidinate CAS 12561-67-0 AND 13870-80-9 MF C12H16CuN6O4 FDA 2026, JAN/12/26, Zycubo, To treat Menkes disease, APPROVALS 2026, 9078K3MO9U, MN 88, CUTX 101 copper bis((2S)-2-amino-3-(1H-imidazol-5-yl)propanoate)…
Idrebormilast CAS 2415085-44-6 MF C18H22BNO4, MW 327.18 Pyridine, 3-[(4R)-2-hydroxy-1,2-oxaborolan-4-yl]-5-(4-methoxy-3-propoxyphenyl)- (4R)-4-[5-(4-methoxy-3-propoxyphenyl)pyridin-3-yl]-1,2-oxaborolan-2-olphosphodiesterase 4 (PDE4) inhibitor, non-steroidal anti-inflammatory, M6ZU548FWD, PF07038124, PF 07038124 PF-07038124 is under investigation in clinical…
Gridegalutamide CAS 2446929-86-6 MF C41H45F3N8O5S MW818.9 g/mol 2-[(2R)-4-[2-[4-[3-[4-cyano-3-(trifluoromethyl)phenyl]-5,5-dimethyl-4-oxo-2-sulfanylideneimidazolidin-1-yl]-2-ethylphenoxy]ethyl]-2-methylpiperazin-1-yl]-N-[3-[[(3R)-2,6-dioxopiperidin-3-yl]amino]phenyl]acetamide antiandrogen, antineoplastic, BMS 986365, CC 94676, BMS-986365, CC-94676, CEL 010355, VA228VR2DI, Gridegalutamide is an investigational oral androgen receptor (AR) degrader being…
Glasmacinal CAS 2097822-02-9 MF C37H62N2O10 MW694.90 [(2S,3R,4S,6R)-4-(dimethylamino)-2-[[(2R,3S,4R,5R,8R,10R,11R,12S,13S,14R)-2-ethyl-3,4,10,13-tetrahydroxy-3,5,6,8,10,12,14-heptamethyl-15-oxo-1-oxa-6-azacyclopentadec-11-yl]oxy]-6-methyloxan-3-yl] benzoate (2R,3S,4R,5R,8R,10R,11R,12S,13S,14R)-11-{[2-O-benzoyl-3,4,6-trideoxy-3-(dimethylamino) -β-D-xylo-hexopyranosyl]oxy}-2-ethyl3,4,10,13-tetrahydroxy-3,5,6,8,10,12,14-heptamethyl-1-oxa-6-azacyclopentadecan-15-onenon-antibacterial macrolide, anti-inflammatory, EP 395, M3T8D3P634 SYN https://patentscope.wipo.int/search/en/detail.jsf?docId=US234729681&_cid=P12-MKVZ26-57135-1 Example 2: (2S,3R,4S,6R)-4-(dimethylamino)-2-[[(2R,3S,4R,5R,8R,10R,11R,12S,13S,14R)-2-ethyl-3,4,10,13-tetrahydroxy-3,5,6,8,10,12,14-heptamethyl-15-oxo-1-oxa-6-azacyclopentadec-11-yl]oxy]-6-methyl-tetrahydropyran-3-yl] benzoate) To a mixture of…
“Patents are good for 20 years after the invention…”
Not quite correct, a US patent term is now in line with the practice in most countries. It’s a 20 year term from the grant. Also for pharmaceuticals, there are possible patent term extensions of up to 5 years under Hatch-Waxman. It should also be noted that FDA can grant patent-like exclusivity, which varies depending on the circumstance.
LikeLike
Reblogged this on MEDCHEMEGYPT.
LikeLike
Reblogged this on MedCheminAustralia.
LikeLike
Reblogged this on MariaGairos–DRUGS.
LikeLike
Reblogged this on MedCheminSingapore by Sushma Wang.
LikeLike
Reblogged this on MED.CHEM in BURMA.
LikeLike
Reblogged this on Med.Chem.in.Iceland.
LikeLike